Grace Therapeutics, Inc. (GRCE): R&D Expense
$2.40M
Year ended 2026-03-31
$2.15M
Trailing 12 months to 2026-06-30
-37.8%
3-year compound annual growth
-10.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $2.40M | -74.7% | 2026-06-18, From 2025-04-01 |
| 2025-03-31 | $9.51M | +103.1% | 2026-06-18, From 2024-04-01 |
| 2024-03-31 | $4.68M | -53.0% | 2025-06-23, From 2023-04-01 |
| 2023-03-31 | $9.97M | +79.4% | 2024-06-21, From 2022-04-01 |
| 2022-03-31 | $5.56M | +33.2% | 2023-06-23, From 2021-04-01 |
| 2021-03-31 | $4.17M | -73.9% | 2022-06-21, From 2020-04-01 |
| 2020-03-31 | $15.97M | -45.6% | 2021-06-22, From 2019-04-01 |
| 2019-03-31 | $29.37M | n/a | 2020-06-29, From 2018-04-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $2.40M | -74.7% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $31.86M | +40.3% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $38.47M | -60.2% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $44.83M | -20.6% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $33.72M | +73.9% |
| Rallybio Corp (RLYB) | 2025-12-31 | $19.60M | -52.8% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $48.26M | +10.2% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $1.00M | -28.6% |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $24.77M | -38.8% |
Compare GRCE, CNTX, SPRO, HOWL side by side · Screen every company in Pharmaceutical Preparations ↗